Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 3
2020 2
2021 5
2022 7
2023 6
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy.
Taha Z, Crupi MJF, Alluqmani N, MacKenzie D, Vallati S, Whelan JT, Fareez F, Alwithenani A, Petryk J, Chen A, Spinelli MM, Ng K, Sobh J, de Souza CT, Bharadwa PR, Lee TKH, Thomas DA, Huang BZ, Kassas O, Poutou J, Gilchrist VH, Boulton S, Thomson M, Marius R, Hooshyar M, McComb S, Arulanandam R, Ilkow CS, Bell JC, Diallo JS. Taha Z, et al. Nat Commun. 2024 Aug 23;15(1):7267. doi: 10.1038/s41467-024-51498-0. Nat Commun. 2024. PMID: 39179564 Free PMC article.
Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy.
Wedge ME, Jennings VA, Crupi MJF, Poutou J, Jamieson T, Pelin A, Pugliese G, de Souza CT, Petryk J, Laight BJ, Boileau M, Taha Z, Alluqmani N, McKay HE, Pikor L, Khan ST, Azad T, Rezaei R, Austin B, He X, Mansfield D, Rose E, Brown EEF, Crawford N, Alkayyal A, Surendran A, Singaravelu R, Roy DG, Migneco G, McSweeney B, Cottee ML, Jacobus EJ, Keller BA, Yamaguchi TN, Boutros PC, Geoffrion M, Rayner KJ, Chatterjee A, Auer RC, Diallo JS, Gibbings D, tenOever BR, Melcher A, Bell JC, Ilkow CS. Wedge ME, et al. Among authors: taha z. Nat Commun. 2022 Apr 7;13(1):1898. doi: 10.1038/s41467-022-29526-8. Nat Commun. 2022. PMID: 35393414 Free PMC article.
The Hippo Pathway: Immunity and Cancer.
Taha Z, Janse van Rensburg HJ, Yang X. Taha Z, et al. Cancers (Basel). 2018 Mar 28;10(4):94. doi: 10.3390/cancers10040094. Cancers (Basel). 2018. PMID: 29597279 Free PMC article. Review.
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy.
Wong B, Bergeron A, Maznyi G, Ng K, Jirovec A, Birdi HK, Serrano D, Spinelli M, Thomson M, Taha Z, Alwithenani A, Chen A, Lorimer I, Vanderhyden B, Arulanandam R, Diallo JS. Wong B, et al. Among authors: taha z. Mol Ther. 2023 Nov 1;31(11):3176-3192. doi: 10.1016/j.ymthe.2023.09.017. Epub 2023 Sep 27. Mol Ther. 2023. PMID: 37766429 Free PMC article.
Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.
Crupi MJF, Taha Z, Janssen TJA, Petryk J, Boulton S, Alluqmani N, Jirovec A, Kassas O, Khan ST, Vallati S, Lee E, Huang BZ, Huh M, Pikor L, He X, Marius R, Austin B, Duong J, Pelin A, Neault S, Azad T, Breitbach CJ, Stojdl DF, Burgess MF, McComb S, Auer R, Diallo JS, Ilkow CS, Bell JC. Crupi MJF, et al. Among authors: taha z. Front Immunol. 2022 Nov 3;13:1029269. doi: 10.3389/fimmu.2022.1029269. eCollection 2022. Front Immunol. 2022. PMID: 36405739 Free PMC article.
CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOX.
Whelan JT, Singaravelu R, Wang F, Pelin A, Tamming LA, Pugliese G, Martin NT, Crupi MJF, Petryk J, Austin B, He X, Marius R, Duong J, Jones C, Fekete EEF, Alluqmani N, Chen A, Boulton S, Huh MS, Tang MY, Taha Z, Scut E, Diallo JS, Azad T, Lichty BD, Ilkow CS, Bell JC. Whelan JT, et al. Among authors: taha z. Front Immunol. 2023 Jan 13;13:1050250. doi: 10.3389/fimmu.2022.1050250. eCollection 2022. Front Immunol. 2023. PMID: 36713447 Free PMC article.
Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen.
Taha Z, Arulanandam R, Maznyi G, Godbout E, Carter-Timofte ME, Kurmasheva N, Reinert LS, Chen A, Crupi MJF, Boulton S, Laroche G, Phan A, Rezaei R, Alluqmani N, Jirovec A, Acal A, Fekete EEF, Singaravelu R, Petryk J, Idorn M, Potts KG, Todesco H, John C, Mahoney DJ, Ilkow CS, Giguère P, Alain T, Côté M, Paludan SR, Olagnier D, Bell JC, Azad T, Diallo JS. Taha Z, et al. Mol Ther. 2022 Sep 7;30(9):2998-3016. doi: 10.1016/j.ymthe.2022.04.025. Epub 2022 May 6. Mol Ther. 2022. PMID: 35526097 Free PMC article.
Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction.
Brown EEF, Rezaei R, Jamieson TR, Dave J, Martin NT, Singaravelu R, Crupi MJF, Boulton S, Tucker S, Duong J, Poutou J, Pelin A, Yasavoli-Sharahi H, Taha Z, Arulanandam R, Surendran A, Ghahremani M, Austin B, Matar C, Diallo JS, Bell JC, Ilkow CS, Azad T. Brown EEF, et al. Among authors: taha z. Int J Mol Sci. 2021 Feb 25;22(5):2268. doi: 10.3390/ijms22052268. Int J Mol Sci. 2021. PMID: 33668756 Free PMC article.
23 results